The peripheral blood leukocyte phenotype in patients with breast cancer: effect of doxorubicin/paclitaxel combination chemotherapy
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
11417845
DOI
10.1081/iph-100103857
Knihovny.cz E-resources
- MeSH
- Lipopolysaccharide Receptors metabolism MeSH
- CD28 Antigens metabolism MeSH
- CD3 Complex metabolism MeSH
- Antigens, CD metabolism MeSH
- CD4-Positive T-Lymphocytes immunology MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Antigens, Differentiation, T-Lymphocyte metabolism MeSH
- Adult MeSH
- Doxorubicin administration & dosage MeSH
- HLA-DR Antigens metabolism MeSH
- Immunophenotyping MeSH
- Lectins, C-Type MeSH
- Leukocytes immunology MeSH
- Middle Aged MeSH
- Humans MeSH
- Breast Neoplasms blood drug therapy immunology MeSH
- Paclitaxel administration & dosage MeSH
- Lymphocyte Subsets immunology MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Receptors, IgG metabolism MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Lipopolysaccharide Receptors MeSH
- CD28 Antigens MeSH
- CD3 Complex MeSH
- Antigens, CD MeSH
- CD69 antigen MeSH Browser
- Antigens, Differentiation, T-Lymphocyte MeSH
- Doxorubicin MeSH
- HLA-DR Antigens MeSH
- Lectins, C-Type MeSH
- Paclitaxel MeSH
- Receptors, IgG MeSH
Presence of functional immune system is critical for any attempt aimed at improving survival of breast cancer patients by strategies based on immune system manipulation. We evaluated by flow cytometry the phenotype of peripheral blood leukocyte of 43 breast cancer patients. In 11 patients, the phenotype was evaluated before and during the chemotherapy by combination of doxorubicin and paclitaxel (AT). Compared with controls breast cancer patients had significantly higher relative and absolute numbers of CD3 HLA-DR+, CD3+CD69+ and CD14+CD16+, and significantly lower percentages of CD3 and CD8+CD28+ cells. After one cycle of AT, the absolute numbers of CD3 , CD3+CD4+, CD3+CD8+ and CD8+CD28+ cells increased significantly. Present data show a presence of T-cell activation in breast cancer patients. Administration of AT may lead to an increase in functional T-cells in peripheral blood, indicating a potential for combining chemotherapy with immunotherapy in the treatment of breast cancer patients.
References provided by Crossref.org
